Skip to main content
. Author manuscript; available in PMC: 2023 Apr 7.
Published in final edited form as: Mol Cancer Ther. 2022 Oct 7;21(10):1573–1582. doi: 10.1158/1535-7163.MCT-22-0192

Figure 6: The PK/PD model accurately predicts the tumor response to trastuzumab gelonin treatment:

Figure 6:

Simulated tumor profiles following treatment with (A) PBS, (B) 2.5 mg/kg trastuzumab-gelonin, (C) 2.5 mg/kg trastuzumab-gelonin+LE8, and (D) 2.5 mg/kg trastuzumab-gelonin+1HE are shown as solid lines. Solid symbols represent observed NCI-N87 tumor volumes for individual xenografts at different timepoints.